

Karin Tarte

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5654879/publications.pdf>

Version: 2024-02-01

182
papers

9,836
citations

28274

55
h-index

40979

93
g-index

194
all docs

194
docs citations

194
times ranked

14267
citing authors

#	ARTICLE	IF	CITATIONS
1	Neutrophil function and bactericidal activity against <i>Staphylococcus aureus</i> after cardiac surgery with cardiopulmonary bypass. <i>Journal of Leukocyte Biology</i> , 2022, 111, 867-876.	3.3	2
2	Safety and preliminary efficacy of allogeneic bone marrow-derived multipotent mesenchymal stromal cells for systemic sclerosis: a single-centre, open-label, dose-escalation, proof-of-concept, phase 1/2 study. <i>Lancet Rheumatology</i> , The, 2022, 4, e91-e104.	3.9	14
3	PIM2 kinase has a pivotal role in plasmablast generation and plasma cell survival, opening up novel treatment options in myeloma. <i>Blood</i> , 2022, 139, 2316-2337.	1.4	5
4	CD40L-expressing CD4+ T cells prime adipose-derived stromal cells to produce inflammatory chemokines. <i>Cytotherapy</i> , 2022, 24, 500-507.	0.7	5
5	Beneficial effects of citrulline enteral administration on sepsis-induced T cell mitochondrial dysfunction. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	7.1	13
6	Molecular Networking for Drug Toxicities Studies: The Case of Hydroxychloroquine in COVID-19 Patients. <i>International Journal of Molecular Sciences</i> , 2022, 23, 82.	4.1	11
7	The EHA Research Roadmap: Malignant Lymphoid Diseases. <i>HemaSphere</i> , 2022, 6, e726.	2.7	1
8	Follicular lymphoma dynamics. <i>Advances in Immunology</i> , 2021, 150, 43-103.	2.2	19
9	Venoarterial extracorporeal membrane oxygenation induces early immune alterations. <i>Critical Care</i> , 2021, 25, 9.	5.8	22
10	SARS-CoV-2-Induced ARDS Associates with MDSC Expansion, Lymphocyte Dysfunction, and Arginine Shortage. <i>Journal of Clinical Immunology</i> , 2021, 41, 515-525.	3.8	87
11	Extracellular vesicles shed by follicular lymphoma B cells promote polarization of the bone marrow stromal cell niche. <i>Blood</i> , 2021, 138, 57-70.	1.4	19
12	Un exemple de tolérance: l'immunologie de la grossesse. <i>Revue Du Rhumatisme Monographies</i> , 2021, 88, 8-12.	0.0	0
13	Mesenchymal stromal cells for systemic sclerosis treatment. <i>Autoimmunity Reviews</i> , 2021, 20, 102755.	5.8	28
14	Lenalidomide triggers T-cell effector functions in vivo in patients with follicular lymphoma. <i>Blood Advances</i> , 2021, 5, 2063-2074.	5.2	11
15	Comparative immune profiling of acute respiratory distress syndrome patients with or without SARS-CoV-2 infection. <i>Cell Reports Medicine</i> , 2021, 2, 100291.	6.5	17
16	B cell/stromal cell crosstalk in health, disease, and treatment: Follicular lymphoma as a paradigm. <i>Immunological Reviews</i> , 2021, 302, 273-285.	6.0	10
17	Mesenchymal stromal cell variables influencing clinical potency: the impact of viability, fitness, route of administration and host predisposition. <i>Cytotherapy</i> , 2021, 23, 368-372.	0.7	45
18	Mass Cytometry Identifies Expansion of T-bet+ B Cells and CD206+ Monocytes in Early Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2021, 12, 653577.	4.8	19

#	ARTICLE	IF	CITATIONS
19	Consensus International Council for Commonality in Blood Banking Automation“International Society for Cell & Gene Therapy statement on standard nomenclature abbreviations for the tissue of origin of mesenchymal stromal cells. <i>Cytotherapy</i> , 2021, 23, 1060-1063.	0.7	15
20	Follicular lymphoma triggers phenotypic and functional remodeling of the human lymphoid stromal cell landscape. <i>Immunity</i> , 2021, 54, 1788-1806.e7.	14.3	43
21	A novel 3D culture model recapitulates primary FL B-cell features and promotes their survival. <i>Blood Advances</i> , 2021, 5, 5372-5386.	5.2	18
22	The flawless immune tolerance of pregnancy. <i>Joint Bone Spine</i> , 2021, 88, 105205.	1.6	3
23	High-Dimensional Phenotyping of Human Myeloid-Derived Suppressor Cells/Tumor-Associated Macrophages in Tissue by Mass Cytometry. <i>Methods in Molecular Biology</i> , 2021, 2236, 57-66.	0.9	5
24	Fam72a enforces error-prone DNA repair during antibody diversification. <i>Nature</i> , 2021, 600, 329-333.	27.8	26
25	Committed Human CD23-Negative Light-Zone Germinal Center B Cells Delineate Transcriptional Program Supporting Plasma Cell Differentiation. <i>Frontiers in Immunology</i> , 2021, 12, 744573.	4.8	7
26	Bone Marrow Lymphoid Niche Adaptation to Mature B Cell Neoplasms. <i>Frontiers in Immunology</i> , 2021, 12, 784691.	4.8	8
27	Nonclassical Monocytes Are Prone to Migrate Into Tumor in Diffuse Large B-Cell Lymphoma. <i>Frontiers in Immunology</i> , 2021, 12, 755623.	4.8	5
28	Integrated transcriptomic, phenotypic, and functional study reveals tissue-specific immune properties of mesenchymal stromal cells. <i>Stem Cells</i> , 2020, 38, 146-159.	3.2	50
29	Epigenetic mechanisms driving tumor supportive microenvironment differentiation and function: a role in cancer therapy?. <i>Epigenomics</i> , 2020, 12, 157-169.	2.1	13
30	Integrative Analysis of Cell Crosstalk within Follicular Lymphoma Cell Niche: Towards a Definition of the FL Supportive Synapse. <i>Cancers</i> , 2020, 12, 2865.	3.7	14
31	Human Lymphoid Stromal Cells Contribute to Polarization of Follicular T Cells Into IL-4 Secreting Cells. <i>Frontiers in Immunology</i> , 2020, 11, 559866.	4.8	7
32	Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response. <i>Cancer Cell</i> , 2020, 37, 655-673.e11.	16.8	93
33	Single-Cell Analysis Reveals Fibroblast Clusters Linked to Immunotherapy Resistance in Cancer. <i>Cancer Discovery</i> , 2020, 10, 1330-1351.	9.4	424
34	AB0034“...EARLY IMMUNIZATION AGAINST TREATMENT IS ASSOCIATED TO POOR CLINICAL RESPONSE AT 6 MONTHS AND LOW NUMBER OF TRANSITIONAL B CELLS AT BASELINE IN RHEUMATOID ARTHRITIS PATIENTS TREATED BY ADALIMUMAB. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1319.1-1320.	0.9	0
35	Lenalidomide Enhance CAR T-Cells Response in Patients with Refractory/Relapsed Large B Cell Lymphoma Experiencing Progression after Infusion. <i>Blood</i> , 2020, 136, 16-17.	1.4	12
36	Adipose mesenchymal stromal cells: Definition, immunomodulatory properties, mechanical isolation and interest for plastic surgery. <i>Annales De Chirurgie Plastique Et Esthetique</i> , 2019, 64, 1-10.	0.6	29

#	ARTICLE	IF	CITATIONS
37	Early-stage myeloid-derived suppressor cell count: Basophil exclusion matters. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 1125-1127.	2.9	7
38	Immunofibroblasts are pivotal drivers of tertiary lymphoid structure formation and local pathology. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 13490-13497.	7.1	115
39	Impact of B cell/lymphoid stromal cell crosstalk in B-cell physiology and malignancy. <i>Immunology Letters</i> , 2019, 215, 12-18.	2.5	14
40	Combination lenalidomide+rituximab immunotherapy activates anti-tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma. <i>British Journal of Haematology</i> , 2019, 185, 240-253.	2.5	39
41	Pan-HDAC Inhibitors Restore PRDM1 Response to IL21 in CREBBP-Mutated Follicular Lymphoma. <i>Clinical Cancer Research</i> , 2019, 25, 735-746.	7.0	21
42	Niveau, a Phase 3 Study for Pts with B- or T-Cell Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivolumab in Combination with Gemcitabine, Oxaliplatin (GemOx), Plus Rituximab (R) in Case of B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 5311-5311.	1.4	0
43	A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. <i>Lancet Oncology</i> , The, 2018, 19, 549-561.	10.7	165
44	Reply to Patel et al.: Tempering the Clinical Effects of Early Myeloid-derived Suppressor Cell Expansion in Severe Sepsis and Septic Shock. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 678-679.	5.6	0
45	NK cell activation and recovery of NK cell subsets in lymphoma patients after obinutuzumab and lenalidomide treatment. <i>Oncolmmunology</i> , 2018, 7, e1409322.	4.6	25
46	Sustained activation of the Aryl hydrocarbon Receptor transcription factor promotes resistance to BRAF-inhibitors in melanoma. <i>Nature Communications</i> , 2018, 9, 4775.	12.8	70
47	CXCR5 and ICOS expression identifies a CD8 T-cell subset with TFH features in Hodgkin lymphomas. <i>Blood Advances</i> , 2018, 2, 1889-1900.	5.2	30
48	Impaired efferocytosis and neutrophil extracellular trap clearance by macrophages in ARDS. <i>European Respiratory Journal</i> , 2018, 52, 1702590.	6.7	132
49	An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma. <i>Blood</i> , 2018, 132, 1486-1494.	1.4	25
50	Designed Surface Topographies Control ICAM-1 Expression in Tonsil-Derived Human Stromal Cells. <i>Frontiers in Bioengineering and Biotechnology</i> , 2018, 6, 87.	4.1	10
51	Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1739-1751.	4.1	87
52	Microenvironment signaling driving lymphomagenesis. <i>Current Opinion in Hematology</i> , 2018, 25, 335-345.	2.5	36
53	Pan-HDAC Inhibitors May Restore PRDM1 Expression in Follicular Lymphoma. <i>Blood</i> , 2018, 132, 2848-2848.	1.4	0
54	Brief Report: Proteasomal Indoleamine 2,3-Dioxygenase Degradation Reduces the Immunosuppressive Potential of Clinical Grade-Mesenchymal Stromal Cells Undergoing Replicative Senescence. <i>Stem Cells</i> , 2017, 35, 1431-1436.	3.2	40

#	ARTICLE	IF	CITATIONS
55	Early Expansion of Circulating Granulocytic Myeloid-derived Suppressor Cells Predicts Development of Nosocomial Infections in Patients with Sepsis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 315-327.	5.6	184
56	IL-4/CXCL12 loop is a key regulator of lymphoid stroma function in follicular lymphoma. <i>Blood</i> , 2017, 129, 2507-2518.	1.4	80
57	Follicular lymphoma: State-of-the-art ICML workshop in Lugano 2015. <i>Hematological Oncology</i> , 2017, 35, 397-407.	1.7	11
58	Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients. <i>Leukemia</i> , 2017, 31, 988-991.	7.2	41
59	Frontline Science: HMGB1 induces neutrophil dysfunction in experimental sepsis and in patients who survive septic shock. <i>Journal of Leukocyte Biology</i> , 2017, 101, 1281-1287.	3.3	55
60	GENE-EXPRESSION PROFILING PREDICTS DISEASE PROGRESSION IN FOLLICULAR LYMPHOMA. <i>Hematological Oncology</i> , 2017, 35, 113-115.	1.7	2
61	Bone marrow mesenchymal stromal cell (MSC) gene profiling in chronic myeloid leukemia (CML) patients at diagnosis and in deep molecular response induced by tyrosine kinase inhibitors (TKIs). <i>Leukemia Research</i> , 2017, 60, 94-102.	0.8	19
62	IL-2 imprints human naive B cell fate towards plasma cell through ERK/ELK1-mediated BACH2 repression. <i>Nature Communications</i> , 2017, 8, 1443.	12.8	77
63	Regulatory myeloid cells: an underexplored continent in B-cell lymphomas. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1103-1111.	4.2	19
64	Role of the microenvironment across histological subtypes of NHL. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 610-617.	2.5	22
65	Impact of Chronic Viral Infection on T-Cell Dependent Humoral Immune Response. <i>Frontiers in Immunology</i> , 2017, 8, 1434.	4.8	5
66	Characterization of human FCRL4-positive B cells. <i>PLoS ONE</i> , 2017, 12, e0179793.	2.5	21
67	Lenalidomide Treatment Restores In Vivo T Cell Activity in Relapsed/Refractory FL and DLBCL. <i>Blood</i> , 2017, 130, 729-729.	1.4	3
68	Reply: Standardized procedure for bone marrow MSCs preparation for clinical use. <i>Stem Cells</i> , 2016, 34, 1994-1995.	3.2	0
69	Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop. <i>OncImmunology</i> , 2016, 5, e1186323.	4.6	2
70	Targeting netrin-1/DCC interaction in diffuse large B-cell and mantle cell lymphomas. <i>EMBO Molecular Medicine</i> , 2016, 8, 96-104.	6.9	19
71	Role of the tumor microenvironment in regulating apoptosis and cancer progression. <i>Cancer Letters</i> , 2016, 378, 150-159.	7.2	96
72	T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells. <i>Blood</i> , 2016, 128, 1081-1092.	1.4	120

#	ARTICLE	IF	CITATIONS
73	Aryl hydrocarbon receptor-dependent enrichment of a megakaryocytic precursor with a high potential to produce proplatelets. <i>Blood</i> , 2016, 127, 2231-2240.	1.4	54
74	Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells. <i>Cell</i> , 2016, 167, 405-418.e13.	28.9	204
75	Loss of IL-22 inhibits autoantibody formation in collagen-induced arthritis in mice. <i>European Journal of Immunology</i> , 2016, 46, 1404-1414.	2.9	30
76	Peripheral phenotype and gene expression profiles of combined liver-kidney transplant patients. <i>Liver International</i> , 2016, 36, 401-409.	3.9	7
77	Histamine quantification in human plasma using high resolution accurate mass LC-MS technology. <i>Clinical Biochemistry</i> , 2016, 49, 111-116.	1.9	6
78	Comparison of two enzymatic immunoassays, high resolution mass spectrometry method and radioimmunoassay for the quantification of human plasma histamine. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 118, 307-314.	2.8	18
79	Liposuction Preserves the Morphological Integrity of the Microvascular Network: Flow Cytometry and Confocal Microscopy Evidence in a Controlled Study. <i>Aesthetic Surgery Journal</i> , 2016, 36, 609-618.	1.6	49
80	CD10 delineates a subset of human IL-4 producing follicular helper T cells involved in the survival of follicular lymphoma B cells. <i>Blood</i> , 2015, 125, 2381-2385.	1.4	61
81	DC-SIGN-expressing macrophages trigger activation of mannosylated IgM B-cell receptor in follicular lymphoma. <i>Blood</i> , 2015, 126, 1911-1920.	1.4	109
82	Cell-Cycle-Dependent Reconfiguration of the DNA Methylome during Terminal Differentiation of Human B Cells into Plasma Cells. <i>Cell Reports</i> , 2015, 13, 1059-1071.	6.4	65
83	Hypoxia Differentially Modulates the Genomic Stability of Clinical-Grade ADSCs and BM-MSCs in Long-Term Culture. <i>Stem Cells</i> , 2015, 33, 3608-3620.	3.2	39
84	Immune Dysfunction After Cardiac Surgery with Cardiopulmonary Bypass. <i>Shock</i> , 2015, 44, 228-233.	2.1	37
85	Self-Restrained B Cells Arise following Membrane IgE Expression. <i>Cell Reports</i> , 2015, 10, 900-909.	6.4	57
86	ING1b negatively regulates HIF1 α protein levels in adipose-derived stromal cells by a SUMOylation-dependent mechanism. <i>Cell Death and Disease</i> , 2015, 6, e1612-e1612.	6.3	9
87	Localized Store-Operated Calcium Influx Represses CD95-Dependent Apoptotic Effects of Rituximab in Non-Hodgkin B Lymphomas. <i>Journal of Immunology</i> , 2015, 195, 2207-2215.	0.8	26
88	GenomicScope: An Easy-to-Use Web Tool for Gene Expression Data Analysis. Application to Investigate the Molecular Events in the Differentiation of B Cells into Plasma Cells. <i>PLoS Computational Biology</i> , 2015, 11, e1004077.	3.2	109
89	Lectin-like transcript 1 is a marker of germinal center-derived B-cell non-Hodgkin's lymphomas dampening natural killer cell functions. <i>Oncolmmunology</i> , 2015, 4, e1026503.	4.6	33
90	Emergence of long-lived autoreactive plasma cells in the spleen of primary warm auto-immune hemolytic anemia patients treated with rituximab. <i>Journal of Autoimmunity</i> , 2015, 62, 22-30.	6.5	40

#	ARTICLE	IF	CITATIONS
91	Effects of a Ceramic Biomaterial on Immune Modulatory Properties and Differentiation Potential of Human Mesenchymal Stromal Cells of Different Origin. <i>Tissue Engineering - Part A</i> , 2015, 21, 767-781.	3.1	15
92	Flow Cytometric Detection and Isolation of Human Tonsil or Lymph Node T Follicular Helper Cells. <i>Methods in Molecular Biology</i> , 2015, 1291, 163-173.	0.9	16
93	T-Cell Defect in Diffuse Large B-Cell Lymphomas Involves Expansion of Myeloid Derived Suppressor Cells Expressing IL-10, PD-L1, and S100A12. <i>Blood</i> , 2015, 126, 1478-1478.	1.4	1
94	Neutrophils trigger a NF- κ B dependent polarization of tumor-supportive stromal cells in germinal center B-cell lymphomas. <i>Oncotarget</i> , 2015, 6, 16471-16487.	1.8	60
95	COX-2-Independent Effects of Celecoxib Sensitize Lymphoma B Cells to TRAIL-Mediated Apoptosis. <i>Clinical Cancer Research</i> , 2014, 20, 2663-2673.	7.0	35
96	IL-6 supports the generation of human long-lived plasma cells in combination with either APRIL or stromal cell-soluble factors. <i>Leukemia</i> , 2014, 28, 1647-1656.	7.2	109
97	High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. <i>Leukemia</i> , 2014, 28, 2367-2375.	7.2	281
98	The yin and the yang of follicular lymphoma cell niches: Role of microenvironment heterogeneity and plasticity. <i>Seminars in Cancer Biology</i> , 2014, 24, 23-32.	9.6	82
99	Human t(14;18)positive germinal center B cells: a new step in follicular lymphoma pathogenesis?. <i>Blood</i> , 2014, 123, 3462-3465.	1.4	44
100	Le polynucléaire basophile: nouveautés en physiopathologie et implications diagnostiques. <i>Revue Francophone Des Laboratoires</i> , 2014, 2014, 95-105.	0.0	1
101	Unique B Cell Differentiation Profile in Tolerant Kidney Transplant Patients. <i>American Journal of Transplantation</i> , 2014, 14, 144-155.	4.7	131
102	The Chronic Lymphocytic Leukemia Clone Disrupts the Bone Marrow Microenvironment. <i>Stem Cells and Development</i> , 2014, 23, 2972-2982.	2.1	18
103	Effects of a novel ceramic biomaterial on immune modulatory properties and differentiation potential of mesenchymal stromal cells. <i>Cytotherapy</i> , 2014, 16, S90-S91.	0.7	0
104	A catalytic-independent role for the LUBAC in NF- κ B activation upon antigen receptor engagement and in lymphoma cells. <i>Blood</i> , 2014, 123, 2199-2203.	1.4	105
105	Germinal center reentries of BCL2-overexpressing B cells drive follicular lymphoma progression. <i>Journal of Clinical Investigation</i> , 2014, 124, 5337-5351.	8.2	96
106	DC-SIGN Binds Preferentially Highly Glycosylated IgM to Trigger Classical BCR Signaling in Follicular Lymphoma. <i>Blood</i> , 2014, 124, 2968-2968.	1.4	2
107	Emergence of Long-Lived Autoreactive Plasma Cells in the Spleen of Primary Warm Auto-Immune Hemolytic Anemia Patients Treated with Rituximab. <i>Blood</i> , 2014, 124, 569-569.	1.4	1
108	The class-specific BCR tonic signal modulates lymphomagenesis in ac-mycderegulation transgenic model. <i>Oncotarget</i> , 2014, 5, 8995-9006.	1.8	10

#	ARTICLE	IF	CITATIONS
109	Comparative Study of Immune Regulatory Properties of Stem Cells Derived from Different Tissues. <i>Stem Cells and Development</i> , 2013, 22, 2990-3002.	2.1	89
110	Immunoregulatory properties of clinical grade mesenchymal stromal cells: evidence, uncertainties, and clinical application. <i>Stem Cell Research and Therapy</i> , 2013, 4, 64.	5.5	61
111	Clinical-Grade Mesenchymal Stromal Cells Produced Under Various Good Manufacturing Practice Processes Differ in Their Immunomodulatory Properties: Standardization of Immune Quality Controls. <i>Stem Cells and Development</i> , 2013, 22, 1789-1801.	2.1	186
112	Risk of tumorigenicity in mesenchymal stromal cellâ€‘based therapiesâ€‘ Bridging scientific observations and regulatory viewpoints. <i>Cytotherapy</i> , 2013, 15, 753-759.	0.7	312
113	Immunological characterization of multipotent mesenchymal stromal cellsâ€‘ The International Society for Cellular Therapy (ISCT) working proposal. <i>Cytotherapy</i> , 2013, 15, 1054-1061.	0.7	364
114	Indoleamine 2,3-dioxygenase activity as a potential biomarker of immune suppression during visceral leishmaniasis. <i>Innate Immunity</i> , 2013, 19, 564-568.	2.4	15
115	ROQUIN/RC3H1 Alterations Are Not Found in Angioimmunoblastic T-Cell Lymphoma. <i>PLoS ONE</i> , 2013, 8, e64536.	2.5	15
116	Blood Soluble PD-L1 Protein In Aggressive Diffuse Large B-Cell Lymphoma Impacts patientâ€™s Overall Survival. <i>Blood</i> , 2013, 122, 361-361.	1.4	4
117	Effects Of a Novel Ceramic Biomaterial On Immune Modulatory Properties and Differentiation Potential Of Mesenchymal Stromal Cells. <i>Blood</i> , 2013, 122, 4858-4858.	1.4	0
118	Quality Controls Of Immune Regulatory Properties Of Ex-Vivo, GMP-Grade Expanded Mesenchymal Stromal Cells For Clinical Use. <i>Blood</i> , 2013, 122, 5413-5413.	1.4	0
119	Immune Regulatory Properties Are a Common Feature Of Stem Cells. <i>Blood</i> , 2013, 122, 5419-5419.	1.4	0
120	Stromal Cell Contribution to Human Follicular Lymphoma Pathogenesis. <i>Frontiers in Immunology</i> , 2012, 3, 280.	4.8	46
121	High rate of TNFRSF14 gene alterations related to 1p36 region in de novo follicular lymphoma and impact on prognosis. <i>Leukemia</i> , 2012, 26, 559-562.	7.2	97
122	Anti-CD20 IgA can protect mice against lymphoma development: evaluation of the direct impact of IgA and cytotoxic effector recruitment on CD20 target cells. <i>Haematologica</i> , 2012, 97, 1686-1694.	3.5	34
123	Limited Acquisition of Chromosomal Aberrations in Human Adult Mesenchymal Stromal Cells. <i>Cell Stem Cell</i> , 2012, 10, 9-10.	11.1	87
124	Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells. <i>Leukemia</i> , 2012, 26, 1053-1063.	7.2	163
125	IL-2 Requirement for Human Plasma Cell Generation: Coupling Differentiation and Proliferation by Enhancing MAPKâ€™ERK Signaling. <i>Journal of Immunology</i> , 2012, 189, 161-173.	0.8	93
126	Mesenchymal stromal cells orchestrate follicular lymphoma cell niche through the CCL2-dependent recruitment and polarization of monocytes. <i>Blood</i> , 2012, 119, 2556-2567.	1.4	133

#	ARTICLE	IF	CITATIONS
127	Monocytes and T cells cooperate to favor normal and follicular lymphoma B-cell growth: role of IL-15 and CD40L signaling. <i>Leukemia</i> , 2012, 26, 139-148.	7.2	77
128	Iterative Germinal Center Re-Entries of Memory B-Cells with t(14;18) Translocation and Early Steps of Follicular Lymphoma Progression. <i>Blood</i> , 2012, 120, 150-150.	1.4	3
129	Molecular Characterization of the Leukemic Niche in Chronic Myeloid Leukemia (CML) and Evaluation of a Leukemia / Niche Cross-Talk. <i>Blood</i> , 2012, 120, 908-908.	1.4	0
130	Characterization of a Transitional Preplasmablast Population in the Process of Human B Cell to Plasma Cell Differentiation. <i>Journal of Immunology</i> , 2011, 187, 3931-3941.	0.8	123
131	Labeling of mesenchymal stromal cells with iron oxideâ€“poly(l-lactide) nanoparticles for magnetic resonance imaging: uptake, persistence, effects on cellular function and magnetic resonance imaging properties. <i>Cytotherapy</i> , 2011, 13, 962-975.	0.7	30
132	2.43 Mesenchymal Progenitors from Chronic Lymphocytic Leukemia Bone Marrow Aspirates are Rare and Display an Altered Phenotype. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S186-S187.	0.4	0
133	Good Manufacturing Practices Production of Mesenchymal Stem/Stromal Cells. <i>Human Gene Therapy</i> , 2011, 22, 19-26.	2.7	196
134	Response to Reinhardt <i>et al.</i>. <i>Human Gene Therapy</i> , 2011, 22, 776-776.	2.7	4
135	Microporous Biphasic Calcium Phosphate Granules (MBCPÂ®) Retain Immunological Properties of Bone Marrow-Derived Mesenchymal Stromal Cells and Promote Osteoblastic Differentiation. <i>Blood</i> , 2011, 118, 1924-1924.	1.4	1
136	Mesenchymal Stromal Cells Orchestrate Follicular Lymphoma Cell Niche Through the CCL2-Dependent Recruitment and Polarization of Monocytes. <i>Blood</i> , 2011, 118, 1566-1566.	1.4	0
137	Quality Controls of Immune Regulatory Properties of Ex-Vivo, GMP-Grade Expanded Mesenchymal Stromal Cells for Clinical Use (European multicenter study CASCADE),. <i>Blood</i> , 2011, 118, 4049-4049.	1.4	0
138	Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. <i>Blood</i> , 2010, 115, 1549-1553.	1.4	403
139	Genomic stability in clinical scale expanded mesenchymal stem/stromal cells. <i>ISBT Science Series</i> , 2010, 5, 212-212.	1.1	0
140	92: Bone Marrow Mesenchymal Stem Cells are altered in CLL. <i>Bulletin Du Cancer</i> , 2010, 97, S75-S76.	1.6	0
141	Enhanced Indoleamine 2,3â€“Dioxygenase Activity in Patients with Severe Sepsis and Septic Shock. <i>Journal of Infectious Diseases</i> , 2010, 201, 956-966.	4.0	66
142	Follicular lymphoma cell niche: identification of a preeminent IL-4-dependent TFHâ€“B cell axis. <i>Leukemia</i> , 2010, 24, 2080-2089.	7.2	133
143	Follicular Lymphoma-Like B Cells In Healthy Individuals Are Released From Pretumoral Niches Established In Secondary Lymphoid Tissues. <i>Blood</i> , 2010, 116, 466-466.	1.4	4
144	CXCR4 Expression Functionally Discriminates Centroblasts versus Centrocytes within Human Germinal Center B Cells. <i>Journal of Immunology</i> , 2009, 182, 7595-7602.	0.8	102

#	ARTICLE	IF	CITATIONS
145	Functional Alteration of the Lymphoma Stromal Cell Niche by the Cytokine Context: Role of Indoleamine-2,3 Dioxygenase. <i>Cancer Research</i> , 2009, 69, 3228-3237.	0.9	76
146	Follicular Lymphoma Cell Niche: Identification of a Preeminent IL-4-Dependent TFH- B Cell Axis.. <i>Blood</i> , 2009, 114, 757-757.	1.4	0
147	CD40 Ligand Protects from TRAIL-Induced Apoptosis in Follicular Lymphomas through NF- κ B Activation and Up-Regulation of c-FLIP and Bcl-xL. <i>Journal of Immunology</i> , 2008, 181, 1001-1011.	0.8	75
148	Aneuploidy in Clinical-Grade Mesenchymal Stem Cells Is Not Linked to Cell Transformation and Not Related to Culture Method. <i>Blood</i> , 2008, 112, 3463-3463.	1.4	0
149	Bone Marrow Mesenchymal Stem Cells Are Altered in B-Cell Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2008, 112, 2066-2066.	1.4	0
150	Human mesenchymal stem cells isolated from bone marrow and lymphoid organs support tumor B-cell growth: role of stromal cells in follicular lymphoma pathogenesis. <i>Blood</i> , 2007, 109, 693-702.	1.4	228
151	B7-1 and 4-1BB ligand expression on a myeloma cell line makes it possible to expand autologous tumor-specific cytotoxic T cells in vitro. <i>Experimental Hematology</i> , 2007, 35, 443-453.	0.4	25
152	Gene Expression Profiling of Highly Purified Malignant and Non-Malignant Cells: Characterization of the Tumor-Microenvironment Cellular Synapse in De Novo Follicular Lymphoma (FL).. <i>Blood</i> , 2007, 110, 355-355.	1.4	2
153	Quantitative and Functional Alterations of the Gamma Delta T-Cell Subset within Follicular Lymphoma Microenvironment.. <i>Blood</i> , 2007, 110, 2601-2601.	1.4	0
154	Microarray-based understanding of normal and malignant plasma cells. <i>Immunological Reviews</i> , 2006, 210, 86-104.	6.0	56
155	Functional Regulatory T Cells Are Collected in Stem Cell Autografts by Mobilization with High-Dose Cyclophosphamide and Granulocyte Colony-Stimulating Factor. <i>Journal of Immunology</i> , 2006, 176, 6631-6639.	0.8	59
156	CD40L Modulates TRAIL-Induced Apoptosis in Germinal Center Derived B Cell Lymphomas.. <i>Blood</i> , 2006, 108, 4630-4630.	1.4	0
157	Human Mesenchymal Stem Cells Isolated from Bone Marrow and Lymphoid Organs Support Tumor B-Cell Growth: Implications in Follicular Lymphoma Pathogenesis.. <i>Blood</i> , 2006, 108, 2409-2409.	1.4	0
158	Influence of Inflammatory Factors Produced during Graft-Versus-Host Disease on Immunological Properties of Mesenchymal Stem Cells (MSC).. <i>Blood</i> , 2006, 108, 3241-3241.	1.4	0
159	Regulatory and Activated T Cells in Stem Cell Autografts Collected by Mobilization with High-Dose Cyclophosphamide and Granulocyte Colony Stimulating Factor.. <i>Blood</i> , 2005, 106, 5216-5216.	1.4	0
160	IFN- γ , Unlike TNF- α , LPS, or CD40 Signal, Is Required and Sufficient To Induce Indoleamine 2,3-Dioxygenase Activity in Mesenchymal Stem Cells.. <i>Blood</i> , 2005, 106, 2311-2311.	1.4	8
161	Human Mesenchymal Stem Cells as Precursors of Functional Fibroblastic Reticular Cells: Implications for the Physiopathology of Secondary Lymphoid Organs.. <i>Blood</i> , 2005, 106, 2310-2310.	1.4	0
162	The Bcl-2 family member Bfl-1/A1 is strongly repressed in normal and malignant plasma cells but is a potent anti-apoptotic factor for myeloma cells. <i>British Journal of Haematology</i> , 2004, 125, 373-382.	2.5	25

#	ARTICLE	IF	CITATIONS
163	BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. <i>Blood</i> , 2004, 103, 3148-3157.	1.4	488
164	Survival and Proliferation Factors of Normal and Malignant Plasma Cells. <i>International Journal of Hematology</i> , 2003, 78, 106-113.	1.6	195
165	Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation. <i>Blood</i> , 2003, 102, 592-600.	1.4	190
166	Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays. <i>Oncogene</i> , 2002, 21, 6848-6857.	5.9	157
167	Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. <i>Blood</i> , 2002, 100, 1113-22.	1.4	59
168	Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays. <i>Blood</i> , 2001, 98, 771-780.	1.4	154
169	JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells. <i>British Journal of Haematology</i> , 2000, 109, 823-828.	2.5	146
170	Extensive characterization of dendritic cells generated in serum-free conditions: regulation of soluble antigen uptake, apoptotic tumor cell phagocytosis, chemotaxis and T cell activation during maturation in vitro. <i>Leukemia</i> , 2000, 14, 2182-2192.	7.2	51
171	Dendritic cell-based vaccine: a promising approach for cancer immunotherapy. <i>Leukemia</i> , 1999, 13, 653-663.	7.2	71
172	Tumor necrosis factor is a survival and proliferation factor for human myeloma cells. <i>European Cytokine Network</i> , 1999, 10, 65-70.	2.0	66
173	Kaposi's sarcoma-associated herpesvirus and multiple myeloma: lack of criteria for causality. <i>Blood</i> , 1999, 93, 3159-63; discussion 3163-4.	1.4	13
174	Induced expression of B7-1 on myeloma cells following retroviral gene transfer results in tumor-specific recognition by cytotoxic T cells. <i>Journal of Immunology</i> , 1999, 163, 514-24.	0.8	25
175	Evidence against KSHV infection in the pathogenesis of multiple myeloma. <i>Virus Research</i> , 1998, 57, 197-202.	2.2	37
176	Impairment of B-lymphocyte differentiation induced by dual triggering of the B-cell antigen receptor and CD40 in advanced HIV-1-disease. <i>Aids</i> , 1998, 12, 1437-1449.	2.2	47
177	Le myélome multiple : un nouveau cancer induit par un virus ?. <i>Medecine/Sciences</i> , 1998, 14, 736.	0.2	2
178	Clinical-grade functional dendritic cells from patients with multiple myeloma are not infected with Kaposi's sarcoma-associated herpesvirus. <i>Blood</i> , 1998, 91, 1852-7.	1.4	10
179	A gp130 interleukin-6 transducer-dependent SCID model of human multiple myeloma. <i>Blood</i> , 1998, 91, 4727-37.	1.4	25
180	Kaposi's sarcoma-associated herpesvirus is not detected with immunosuppression in multiple myeloma. <i>Blood</i> , 1998, 92, 2186-8.	1.4	2

#	ARTICLE	IF	CITATIONS
181	Generation of virtually pure and potentially proliferating dendritic cells from non-CD34 apheresis cells from patients with multiple myeloma. <i>Blood</i> , 1997, 90, 3482-95.	1.4	6
182	Mass Cytometry and Artificial Intelligence Define CD169 as a Marker of SARS-CoV2-Induced Acute Respiratory Distress Syndrome. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0